Crossmark

First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial

Crossref DOI link: https://doi.org/10.1007/s00262-024-03769-4

Published Online: 2024-08-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Qi

Su, Xi

Xue, Jiao

Liu, Yandong

Zhu, Jiaxing

Cai, Xuwei

Qin, Songbing
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (K112201720)

National Natural Science Foundation of China (82073337)

Emerging Advanced Technology Joint Research Project of Shanghai Shenkang Hospital Development Center (SHDC12017103)

Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20161433)

Scientific research project of Suzhou Health Talents (GSWS2020007)

Jiangsu Provincial Medical Key Discipline (ZDXK202235)
License Information

Text and Data Mining valid from 2024-08-06

Version of Record valid from 2024-08-06
More Information

Article History

Received: 13 March 2024

Accepted: 25 June 2024

First Online: 6 August 2024

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

: The study was conducted in accordance with the Declaration of Helsinki and received approval from our Hospital's Ethics Committee on May 16, 2019, and secured its registration at the Clinical Registry.

: All participants provided written informed consent before the study’s commencement.

Document is current

Any future updates will be listed below